Renibus brings Series B total to $72M, securing registrational development for lead heart surgery candidate
Cardiorenal biotech Renibus Therapeutics has completed a Series B extension that brings its total proceeds to $72 million, securing a runway through registrational development and an NDA filing for its lead program.
In July, the Texas-based company raised $47 million in a Series B, but has now increased this amount to $72 million. Renibus did not name investors involved in either portion of the raise, but said in a press release they are “comprised of existing and new investors, including leaders in the cardiac surgery community.” A previous bridge financing for the company was backed by Oxford Finance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.